Wave Life Sciences (NASDAQ:WVE) to Review Q3 2025 Financial Results

CAMBRIDGE, Mass. — November 4, 2025 — Leads & Copy — Wave Life Sciences Ltd. (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Monday, November 10, 2025, to review its third quarter 2025 financial results and provide business updates.

The webcast and conference call can be accessed via the “Investor Events” section of Wave Life Sciences’ website. Analysts planning to participate in the Q&A can join via the provided audio-conferencing link. An archived version will be available on the website after the live event.

Wave Life Sciences focuses on RNA medicines, utilizing its PRISM® platform to deliver scientific breakthroughs for rare and common disorders through editing, splicing, RNA interference, and antisense silencing. Its pipeline includes clinical programs for alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, with preclinical programs using its RNA therapeutics toolkit. Wave aims to “Reimagine Possible” and is headquartered in Cambridge, MA.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

Source: Wave Life Sciences

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.